- Home
- ETON vs BRDG Comparison
ETON vs BRDG Comparison
Compare ETON & BRDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- BRDG
- Stock Information
- Founded
- ETON 2017
- BRDG 2009
- Country
- ETON United States
- BRDG United States
- Employees
- ETON N/A
- BRDG N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- BRDG Investment Managers
- Sector
- ETON Health Care
- BRDG Finance
- Exchange
- ETON Nasdaq
- BRDG Nasdaq
- Market Cap
- ETON 329.8M
- BRDG 464.9M
- IPO Year
- ETON 2018
- BRDG 2021
- Fundamental
- Price
- ETON $13.74
- BRDG $10.36
- Analyst Decision
- ETON Strong Buy
- BRDG Hold
- Analyst Count
- ETON 3
- BRDG 5
- Target Price
- ETON $27.67
- BRDG $11.40
- AVG Volume (30 Days)
- ETON 232.5K
- BRDG 562.2K
- Earning Date
- ETON 03-18-2025
- BRDG 05-07-2025
- Dividend Yield
- ETON N/A
- BRDG 4.44%
- EPS Growth
- ETON N/A
- BRDG N/A
- EPS
- ETON N/A
- BRDG 0.13
- Revenue
- ETON $39,011,000.00
- BRDG $419,220,000.00
- Revenue This Year
- ETON $107.69
- BRDG N/A
- Revenue Next Year
- ETON $65.50
- BRDG $26.25
- P/E Ratio
- ETON N/A
- BRDG $79.39
- Revenue Growth
- ETON 23.29
- BRDG 61.35
- 52 Week Low
- ETON $3.03
- BRDG $6.31
- 52 Week High
- ETON $18.41
- BRDG $11.69
- Technical
- Relative Strength Index (RSI)
- ETON 41.63
- BRDG 63.54
- Support Level
- ETON $12.73
- BRDG $9.14
- Resistance Level
- ETON $15.10
- BRDG $10.53
- Average True Range (ATR)
- ETON 0.98
- BRDG 0.34
- MACD
- ETON -0.05
- BRDG 0.04
- Stochastic Oscillator
- ETON 33.67
- BRDG 90.40
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About BRDG Bridge Investment Group Holdings Inc.
Bridge Investment Group Holdings Inc is a vertically integrated investment manager, diversified across specialized asset classes. The company combines its operating platform with dedicated teams of investment professionals focused on various specialized and synergistic investment platforms, including real estate, credit, renewable energy, and secondaries strategies. Its products and vertically integrated structure allow it to capture new market opportunities and serve investors with various investment objectives. The Company operates as one business, a fully integrated real estate investment manager.